Tag: Biopharma

Calliditas Therapeutics reports strong Q4 growth and sets sights on expansion, with TARPEYO sales surging 170% in 2023. CEO optimistic ...

Johnson & Johnson's $2 billion acquisition of Ambrx Biopharma emphasizes its focus on oncology and targeted cancer treatments. #PharmaNews

Investment in women's health startups has soared 314%, outpacing the overall health sector, according to a report from Silicon Valley ...

Licensing deals and ADCs drive biopharma deal flow in 2023, offering hope to an industry grappling with challenges. Big Pharma's ...

Hansa Biopharma reports Q4 revenue growth and expansion into new markets, with impressive results and increasing demand for their therapeutic ...

CG Oncology files for IPO, aims to revolutionize bladder cancer treatment with cretostimogene, a potential breakthrough therapy for high-risk bladder ...

Arcutis Biotherapeutics receives a Buy rating upgrade from Mizuho Securities, pushing stock up 6% in after-hours trading.

Eli Lilly strengthens its presence in cancer treatment with the completion of its $1.4 billion acquisition of Point Biopharma, expanding ...